Sickle Cell Disease

Clinical Snapshot

Sickle cell disease (SCD) is an autosomal recessive hemoglobinopathy caused by a single point mutation in the beta-globin gene (HBB, Glu6Val) that produces hemoglobin S (HbS). Under deoxygenated conditions HbS polymerizes, rigidifying and deforming red blood cells into the characteristic sickle shape; sickled cells occlude the microvasculature — causing recurrent, severely painful vaso-occlusive crises and progressive organ damage — and hemolyze prematurely, causing chronic anemia. Disease is most severe in HbSS (sickle cell anemia) and HbS-beta0-thalassemia; HbSC and HbS-beta+-thalassemia are generally milder but still carry real risk of every major complication in this chapter, including stroke and retinopathy — never assume a "milder genotype" patient is safe from an acute complication. A single HbS allele without a second abnormal beta-globin allele — sickle cell trait (HbAS) — is a carrier state, not a disease; it is usually asymptomatic and is covered in Special Populations. Functional asplenia from progressive splenic infarction is present in roughly 94% of children with HbSS by age 5, which makes fever in a person with SCD a genuine medical emergency — never a routine complaint to reassure and monitor at home.^[1]^[2]

Recognize the Condition

Typical Presentation

Ranges from an asymptomatic interval between crises to acute, life-threatening complications.

Vaso-occlusive (pain) crisis — the most common acute presentation: severe pain in the back, chest, abdomen, or long bones, often precipitated by cold, dehydration, hypoxia, infection, or stress, though frequently with no identifiable trigger at all.
Dactylitis ("hand-foot syndrome") — painful, symmetric swelling of the hands and/or feet; often the first clinical sign of SCD, typically appearing between 6 and 12 months of age as protective fetal hemoglobin declines.
Chronic hemolytic anemia — pallor, fatigue, jaundice/scleral icterus, and a predisposition to pigment (bilirubin) gallstones from an early age.
Splenic sequestration crisis — sudden, painful splenic enlargement trapping a large volume of blood, causing rapidly worsening anemia and hypovolemic shock; a leading cause of death in young children with SCD.
Aplastic crisis — sudden, severe worsening of anemia with an inappropriately low reticulocyte count, most often triggered by parvovirus B19 infection transiently halting red cell production.
Priapism — a prolonged, unwanted, painful erection from vaso-occlusion within the corpora cavernosa.

Risk Factors

Inheriting two abnormal beta-globin alleles, at least one of which is HbS: HbSS, HbSC, HbS-beta0-thalassemia, or HbS-beta+-thalassemia. Both biological parents must carry at least one abnormal beta-globin allele.
Dehydration.
Hypoxia, including unpressurized high-altitude flight, poorly controlled asthma, and obstructive sleep apnea.
Cold exposure — peripheral vasoconstriction promotes sickling.
Infection and fever — a common vaso-occlusive-crisis trigger as well as a direct threat in its own right.
Physical or emotional stress, and extreme physical exertion.
Pregnancy — see Special Populations.

Red Flags & Refer

Treat any of the following as a genuine emergency requiring immediate assessment — never reassurance and home monitoring:

Fever ≥38°C — functional asplenia means real risk of overwhelming sepsis, classically pneumococcal; needs immediate blood cultures and empiric parenteral antibiotics, not a wait-and-see approach.^[1]
Chest pain, new hypoxia, tachypnea, or cough with fever — suspect acute chest syndrome regardless of how mild the presentation looks; it can progress rapidly.^[3]
Sudden left-upper-quadrant pain or abdominal mass with pallor and tachycardia, especially in a young child — suspect splenic sequestration, which can be fatal within hours.
Focal neurologic deficit, severe headache, seizure, or altered consciousness — suspect stroke; do not attribute to a benign cause, especially in a child, without emergency neuroimaging.
Erection lasting more than 4 hours — priapism is a urologic emergency beyond this point.
Profound fatigue and pallor with a disproportionately low reticulocyte count, often after a recent viral illness — suspect aplastic crisis, which needs transfusion.
Pain not controlled by the patient's own usual home regimen — refer to the emergency department rather than repeating or escalating an over-the-counter recommendation.

Assessment & Diagnosis

Sickle cell genotypes

Genotype	Relative severity	Notes
HbSS (sickle cell anemia)	Most severe	Lowest baseline hemoglobin, highest crisis frequency.
HbS-beta0-thalassemia	Similarly severe to HbSS	No normal beta-globin produced from either allele.
HbSC	Generally milder, but real risk remains	Higher baseline hemoglobin; disproportionately higher risk of retinopathy and avascular necrosis relative to overall crisis frequency.
HbS-beta+-thalassemia	Generally milder	Some normal beta-globin still produced; severity varies with the specific beta+ mutation.
HbAS (sickle cell trait)	Carrier state, not disease	Usually asymptomatic; see Special Populations for the real but uncommon exceptions.

Diagnosis

Definitive diagnosis requires hemoglobin electrophoresis or high-performance liquid chromatography (HPLC) to identify and quantify the specific hemoglobin variants present — this is what distinguishes HbSS from HbSC from HbS-beta-thalassemia, and it is not interchangeable with a rapid sickle solubility test (e.g., Sickledex), which only detects the presence of HbS, cannot distinguish sickle cell disease from sickle cell trait, and can be falsely negative in a newborn (fetal hemoglobin still dominant) or in a severely anemic patient. Do not use a solubility test alone to rule in or rule out SCD.^[2] Newborn screening for hemoglobinopathies is not yet universal across Canadian provinces and territories, so a first presentation can still be a previously undiagnosed infant or child presenting acutely — maintain suspicion in a child of at-risk ancestry presenting with dactylitis, unexplained anemia, or a vaso-occlusive-type pain crisis.^[1]

Baseline and monitoring investigations

CBC with differential and reticulocyte count — baseline hemoglobin is typically well below the normal range (commonly 60-90 g/L in HbSS) with an elevated reticulocyte count reflecting ongoing compensatory red cell production; a reticulocyte count that is inappropriately low for the degree of anemia should raise concern for aplastic crisis.
Peripheral blood smear — sickled cells, target cells, and Howell-Jolly bodies (the latter reflecting functional asplenia).
Annual transcranial Doppler (TCD) ultrasound in children with HbSS or HbS-beta0-thalassemia, generally from age 2 to 16 years, to screen for stroke risk; an abnormal (high-velocity) result is an indication for chronic transfusion to reduce stroke risk.^[2]

Treatment Targets

Prevent and reduce the frequency of vaso-occlusive pain crises and acute chest syndrome.
Prevent stroke, particularly in children.
Prevent and promptly treat infection in a functionally asplenic patient.
Relieve acute pain rapidly and adequately whenever a crisis occurs.
Manage chronic hemolytic anemia and its complications (gallstones, leg ulcers, pulmonary hypertension, renal disease, retinopathy, avascular necrosis).
Monitor for and manage iron overload in transfusion-dependent patients.
Support informed reproductive and genetic-counseling decisions.

Choose Initial Treatment

Direct treatment rule — disease-modifying therapy

Offer and strongly encourage hydroxyurea for essentially every child with HbSS or HbS-beta0-thalassemia from 9 months of age onward, regardless of disease severity, and for every adult with HbSS, HbS-beta0-thalassemia, or HbSC who has had 3 or more crises in a year, an abnormal transcranial Doppler velocity, or evidence of an SCD-related organ complication.^[4] It is genuinely appropriate to consider hydroxyurea even earlier — from 6 months of age — in a symptomatic infant (dactylitis, an acute pain crisis, or severe anemia).^[4]

Direct treatment rule — acute vaso-occlusive pain crisis

Begin analgesia immediately — target the first dose within 30-60 minutes of the patient presenting for care — and individualize the dose and agent to the patient's own prior effective regimen wherever it is known, since many patients with SCD have genuinely elevated opioid requirements from chronic disease and prior exposure, not from misuse. Reassess pain and re-dose at an interval matched to the drug's onset (roughly every 15-30 minutes for IV opioid titration), not a fixed ward schedule, until adequate control is reached.^[5]

Direct treatment rule — infection prevention

Start oral penicillin V prophylaxis in every child with HbSS or HbS-beta0-thalassemia at 2 months of age (or at diagnosis, if diagnosed later) and continue to at least age 5; ensure the child also receives the enhanced pneumococcal, meningococcal, and Hib vaccination schedule recommended for functional asplenia, on top of the routine childhood immunization schedule.^[1]

Non-Pharmacologic Treatment

Maintain adequate hydration at all times — oral in the well patient; IV at maintenance rate only (not aggressive/bolus volumes) during an acute crisis or acute chest syndrome, since overhydration itself worsens outcomes in acute chest syndrome.^[3]
Avoid known triggers where practical: cold exposure, dehydration, hypoxia (including unpressurized high-altitude flight), and extreme physical exertion.
Use incentive spirometry for any patient admitted with chest or back pain, or with any vaso-occlusive crisis — this measurably reduces the risk of developing acute chest syndrome during that admission.^[3]
Apply local heat for pain-crisis comfort as an adjunct to, never a substitute for, adequate systemic analgesia.
Provide genetic counseling for patients and at-risk reproductive partners, and psychosocial support given the real burden of chronic, unpredictable pain.
Educate every patient/caregiver explicitly: any fever must prompt immediate medical assessment, never a wait-and-see approach.

Pharmacologic Treatment Options

Disease-modifying and prophylactic therapy

Drug / intervention	Role	Dose / use	Important adverse effects	Teaching points
Hydroxyurea Preferred	Disease-modifying therapy — reduces crisis frequency, acute chest syndrome, and transfusion need	See Drug Tables for the full starting-dose and titration protocol	Reversible cytopenias, GI upset, skin/nail changes	Standard of care. Start regardless of severity in essentially every child with HbSS/HbS-beta0-thalassemia from 9 months of age (6 months if symptomatic).
Folic acid Preferred	Adjunct — supports the ongoing high red cell turnover of chronic hemolysis	1 mg PO once daily	Generally well tolerated	Give to essentially every patient with SCD, not only those with confirmed deficiency.
Penicillin V Preferred	Infection prophylaxis in children with HbSS/HbS-beta0-thalassemia (functional asplenia)	125 mg PO BID (2 months to 3 years); 250 mg PO BID (3 years and older)	GI upset; true allergy uncommon	Start at 2 months of age, continue to at least age 5; continue indefinitely after invasive pneumococcal disease, splenectomy, or inconsistent adherence.
Voxelotor Not currently available	Was: HbS-polymerization inhibitor	Not applicable	Not applicable	Withdrawn from every world market by Pfizer in September 2024 after a safety signal of increased vaso-occlusive crises and death — not an available treatment option anywhere, including Canada.
Crizanlizumab Not currently available	Was: P-selectin inhibitor, reduces vaso-occlusive crisis frequency	Not applicable	Not applicable	No Health Canada-approved product exists; its EU/UK marketing authorization was withdrawn after the confirmatory STAND trial failed to show benefit over placebo.
L-glutamine Not currently available	Was: oral amino-acid therapy, reduces acute complications	Not applicable	Not applicable	No Health Canada-approved product exists in Canada.

The current model of care is to continue hydroxyurea indefinitely once started and well tolerated. Newer agents are not yet part of Canadian practice — see Common Errors to Avoid before discussing them with a patient as though they were accessible options.

Vaso-occlusive crisis analgesia

Drug / intervention	Role	Dose / use	Important adverse effects	Teaching points
Morphine Preferred	First-line opioid for moderate-severe vaso-occlusive pain	IV 0.1-0.15 mg/kg (typical adult range 2.5-10 mg), titrated and repeated roughly every 15-30 minutes to effect	Sedation, constipation, pruritus, respiratory depression at excess dose	Titrate rapidly to effect; individualize upward for a patient with a known, higher, previously effective dose rather than defaulting to a low starting dose for everyone.
Hydromorphone Alternative	Higher-potency alternative, or for a documented morphine intolerance	IV 0.015-0.02 mg/kg, titrated and repeated roughly every 15-30 minutes to effect	Same class effects as morphine, more potent per mg	A reasonable default for a patient with a known high opioid requirement.
Fentanyl Alternative	Rapid onset, or renal impairment (sickle cell nephropathy)	IV 0.5-1 mcg/kg, titrated and repeated roughly every 30-60 minutes to effect	Chest wall rigidity with rapid high-dose push	Minimal active-metabolite accumulation in renal impairment — a genuine advantage in sickle cell nephropathy.
Ketorolac Adjunct	NSAID adjunct when pain is not fully controlled by an opioid alone	IV/IM 15-30 mg every 6 hours, maximum 5 days	Same as oral NSAIDs; avoid in significant renal impairment	Use with caution, or avoid, in a patient with sickle cell nephropathy or an acute-kidney-injury component to the presentation.
Diphenhydramine Adjunct	Opioid-induced pruritus	25-50 mg PO/IV every 6 hours as needed	Sedation, additive with the opioid itself	Treats the itch without needing to reduce effective analgesic dosing — the itch is usually histamine-related, not a true opioid allergy.
Ondansetron Adjunct	Opioid-induced or crisis-associated nausea	4-8 mg IV/PO every 8 hours as needed	Headache; QT prolongation at high doses	Preferred over a sedating antiemetic, which would compound opioid sedation.

Do not use meperidine for vaso-occlusive crisis pain — its neurotoxic metabolite normeperidine accumulates with repeated dosing and causes seizures, a real risk in a population that may need repeated crisis treatment. Tramadol and codeine are also not appropriate first-line agents for a genuinely severe crisis.^[5]

Special Populations

Pregnancy

Pregnancy in SCD is genuinely high-risk: more frequent vaso-occlusive crises and acute chest syndrome, and a higher risk of preeclampsia, fetal growth restriction, and preterm birth. Hydroxyurea is contraindicated in pregnancy — discontinue before a planned conception and ensure effective contraception is in place for anyone of reproductive potential taking it; if ongoing disease-modifying therapy is still needed during pregnancy, chronic transfusion is the alternative.^[4] Continue folic acid throughout pregnancy. Manage pregnancy in SCD jointly with a high-risk obstetric team and hematology, not through routine antenatal care alone.

Breastfeeding

Hydroxyurea is contraindicated while breastfeeding, as it is excreted in breast milk.^[4]

Pediatrics

Start hydroxyurea from 9 months of age regardless of severity (from 6 months if symptomatic), start penicillin V prophylaxis at 2 months, and begin annual TCD screening at age 2. Growth rate has not been shown to be adversely affected by hydroxyurea in pediatric trials.^[4]

Perioperative

Any patient with SCD undergoing surgery requiring general anesthesia is at increased risk of vaso-occlusive and acute chest syndrome complications — involve hematology in perioperative planning, avoid prolonged preoperative fasting and dehydration, and maintain oxygenation and warmth throughout the perioperative period.

Sickle cell trait (HbAS) carriers

Sickle cell trait is usually entirely asymptomatic and is not sickle cell disease — it does not require hydroxyurea, antimicrobial prophylaxis, or SCD-level monitoring. It is not, however, entirely risk-free: rare but real associations exist with exertional rhabdomyolysis and exertional sickling under extreme physical exertion (military and intense athletic training), renal medullary carcinoma, and hematuria from renal papillary necrosis. Its main relevance to a pharmacist is genetic counseling for reproductive partners.

Curative and advanced options

Allogeneic hematopoietic stem cell transplant remains the only long-established cure, with the best outcomes from a matched sibling donor in childhood. Exagamglogene autotemcel (Casgevy), a CRISPR/Cas9 gene-edited autologous cell therapy, received Health Canada marketing authorization in September 2024 for patients 12 years of age and older with recurrent vaso-occlusive crises — a genuine, currently available (though highly specialized, limited-center) option, unlike voxelotor, crizanlizumab, or L-glutamine. Refer a patient with recurrent severe crises despite optimized hydroxyurea to a specialized SCD/transplant centre for eligibility evaluation rather than assuming no further options exist.

Monitoring & Follow-Up

Regular hematology follow-up for all patients; more frequent during hydroxyurea titration (see Drug Tables for the exact schedule).
Annual TCD ultrasound, ages 2-16, in HbSS/HbS-beta0-thalassemia.^[2]
Annual dilated ophthalmologic exam from around age 10 to screen for sickle retinopathy — proportionally more important in HbSC.
Annual urinalysis/albuminuria screening and renal function testing for sickle nephropathy.
Periodic echocardiogram and pulmonary function assessment in adults to screen for pulmonary hypertension.
In transfusion-dependent patients: serial ferritin plus periodic cardiac and liver T2* MRI — MRI is the more reliable measure of true iron burden than ferritin alone — to guide chelation therapy.^[6]
Review vaccination status and hydroxyurea adherence at every visit.

Treatment Failure / Next Step

For an inadequate hydroxyurea response: confirm adherence first, confirm the patient is genuinely at the maximum tolerated dose (not a dose left unescalated by default), and allow a full 6-month trial at that dose before concluding the drug has failed.^[4]
For recurrent severe crises despite an optimized, adherent hydroxyurea regimen: consider chronic transfusion therapy, and refer to a specialized sickle cell/transplant centre to evaluate eligibility for allogeneic hematopoietic stem cell transplant or CRISPR-based gene therapy (exagamglogene autotemcel/Casgevy, Health Canada-approved since September 2024 for age 12 and older with recurrent vaso-occlusive crises) — these are genuine current options, not merely research.
For a vaso-occlusive crisis not adequately controlled by the patient's usual home regimen: refer to the emergency department for parenteral opioid titration rather than repeating or escalating an oral regimen indefinitely at home.
For pain that remains poorly controlled despite reasonable parenteral opioid titration in hospital: reassess for acute chest syndrome, splenic sequestration, or another evolving complication before assuming simple analgesic failure, and involve acute pain/hematology specialists.^[5]

Common Errors to Avoid

Treating fever in a person with SCD as a routine, reassurance-and-monitor complaint — functional asplenia makes this a genuine sepsis risk requiring immediate assessment.
Under-treating vaso-occlusive pain out of concern about opioid misuse — genuine, often high, opioid requirements are a real and expected feature of severe crisis pain, not evidence of drug-seeking behaviour; undertreated pain is real, documented harm.^[5]
Giving iron empirically for the anemia of SCD — patients with SCD are not iron deficient at baseline, and inappropriate iron supplementation on top of chronic hemolysis (and, in transfusion-dependent patients, transfusional iron loading) risks worsening iron overload.
Missing acute chest syndrome in a patient admitted for an uncomplicated-seeming pain crisis — use routine incentive spirometry and oxygen saturation monitoring for every SCD admission, not only once respiratory symptoms are already present.^[3]
Giving aggressive or bolus IV fluids in suspected or confirmed acute chest syndrome — maintenance-rate fluids only; overhydration worsens pulmonary status.^[3]
Using meperidine for vaso-occlusive crisis pain — accumulation of its neurotoxic metabolite normeperidine causes seizures, a particular concern in a population that may receive repeated dosing across multiple admissions.
Assuming sickle cell trait (HbAS) is a form of the disease requiring hydroxyurea, prophylaxis, or crisis-level monitoring — it is a carrier state, not SCD.
Assuming voxelotor, crizanlizumab, or L-glutamine are current, accessible Canadian treatment options to discuss with a patient — none has a Health Canada-approved product, and voxelotor has been withdrawn from every world market.^[7]

Clinical Decision Algorithm

Recognizing a sickle cell emergency

Patient with known or suspected SCD presents with an acute symptom

Fever ≥38°C

Treat as a medical emergency: blood cultures, empiric broad-spectrum/parenteral antibiotics — do not wait for a full assessment

Chest pain, new hypoxia, tachypnea, or cough with fever

Suspect acute chest syndrome: admit, high-flow O2 to target SpO2 ≥95%, maintenance-rate fluids only, chest imaging, blood cultures, urgent hematology consult

Severe pain (vaso-occlusive crisis)

Begin analgesia within 30-60 minutes; individualize the dose to the patient's known effective regimen

Other sickle cell emergencies

Additional presentations that must be recognized immediately

Sudden left-upper-quadrant pain/abdominal mass, pallor, tachycardia (especially a young child)

Suspect splenic sequestration — emergency transfusion; can be fatal within hours

Focal neurologic deficit, severe headache, seizure, or altered consciousness

Suspect stroke — emergency neuroimaging and exchange transfusion; do not attribute to a benign cause, especially in a child

Erection lasting more than 4 hours

Priapism — urologic emergency; do not manage expectantly beyond 4 hours

Vaso-occlusive pain crisis: assessment and treatment

Assess pain severity and screen for red flags: fever, chest/respiratory symptoms, focal neurologic signs, priapism, signs of sequestration

Red flags present

Manage the specific emergency in parallel — see the emergency-recognition algorithms above

Uncomplicated vaso-occlusive pain

Begin analgesia within 30-60 minutes: parenteral opioid at an individualized/titrated dose, plus an NSAID adjunct if not contraindicated

Reassess pain roughly every 15-30 minutes; re-dose/titrate until adequate control, using the patient's own prior effective regimen as a guide

Adequate control reached

Transition to oral analgesia; arrange follow-up; review hydroxyurea adherence and dose

Inadequate control despite reasonable titration

Reassess for acute chest syndrome or another evolving complication; involve hematology/acute pain service — do not simply repeat the same dose indefinitely

Drug Tables

How to use this table: Doses are adult doses unless stated otherwise and require patient-specific confirmation, including renal/hepatic adjustment. Select any drug name to open its complete Pharmasist Drug Database page.

Disease-modifying therapy

Titrate to the maximum tolerated dose for each patient, based on laboratory monitoring and clinical response — the goal is not a fixed target dose but the highest dose the patient's blood counts can safely sustain.

^[4]

Drug	Dosage	Adverse effects	Drug interactions	Comments
Hydroxyurea	Adults, starting dose: 15 mg/kg/day, rounded to the nearest 500 mg capsule Children, starting dose: 20 mg/kg/day; a compounded liquid formulation is available for young children Chronic kidney disease, starting dose: 5-10 mg/kg/day Dose escalation: Increase by 5 mg/kg/day every 8 weeks until the target absolute neutrophil count (ANC) of 2-4 x 10^9/L is reached, or until the maximum tolerated dose is found Target laboratory parameters: ANC ≥2 x 10^9/L (some younger patients tolerate down to 1.25 x 10^9/L); platelets ≥80 x 10^9/L If counts fall below target: Hold the dose, recheck CBC weekly, and restart once counts recover at 5 mg/kg/day below the dose that was held Monitoring during titration: CBC with differential and reticulocyte count at least every 4-8 weeks Monitoring once stable: CBC with differential and reticulocyte count every 8-12 weeks; HbF level every 6 months — do not discontinue hydroxyurea solely because HbF fails to rise, since clinical benefit does not depend on it	Reversible neutropenia/thrombocytopenia, macrocytosis (expected and desired), GI upset, skin/nail changes, reversible oligospermia	No clinically significant drug interactions at standard use; avoid live vaccines while on therapy per routine immunosuppressive-drug precautions	Contraindicated in pregnancy and breastfeeding. Contraception required for all patients of reproductive potential while on therapy. Clinical response may take 3-6 months to appear even once laboratory response (rising MCV, falling WBC/platelets) is evident.

Adjunct supplementation

Drug	Dosage	Adverse effects	Drug interactions	Comments
Folic acid	Adults and children: 1 mg PO once daily	Generally well tolerated	None clinically significant at this dose	Give to essentially every patient with SCD given the chronically increased red cell turnover, not only those with a documented deficiency.

Antimicrobial prophylaxis (children with HbSS/HbS-beta0-thalassemia)

Tablets are preferable to suspension for shelf-life reasons and may be crushed for younger children. Start at 2 months of age and continue to at least age 5; continue indefinitely after invasive pneumococcal disease, surgical splenectomy, incomplete immunization status, or a history of inconsistent adherence.

Drug	Dosage	Adverse effects	Drug interactions	Comments
Penicillin V	2 months to 3 years: 125 mg PO BID 3 years and older: 250 mg PO BID	GI upset; true allergy uncommon	None clinically significant at this dose	First-line antimicrobial prophylaxis.
Amoxicillin	Prophylactic dosing: Equivalent-activity dose to penicillin V, per current pediatric dosing references	GI upset; rash	None clinically significant at this dose	Effective alternative when penicillin V is not available.
Sulfamethoxazole-trimethoprim	Prophylactic dosing: Equivalent-activity dose to penicillin V, per current pediatric dosing references	GI upset, photosensitivity, rare severe cutaneous reactions	Increases warfarin effect; increases methotrexate toxicity; hyperkalemia with ACE inhibitors/ARBs/potassium-sparing diuretics	For a documented penicillin allergy.
Erythromycin	Prophylactic dosing: Equivalent-activity dose to penicillin V, per current pediatric dosing references	GI upset (common); rare QT prolongation	Strong CYP3A4 inhibitor — numerous interactions; avoid with other QT-prolonging drugs	Alternative for a documented penicillin allergy.

^[1]

Immunizations: children with SCD require the full routine childhood schedule plus an enhanced schedule against the encapsulated organisms functional asplenia leaves them vulnerable to — pneumococcal conjugate and polysaccharide vaccines, meningococcal conjugate (ACYW) and serogroup B vaccines, and a booster dose of Hib conjugate vaccine from age 5 — together with annual influenza and, where not already given in infancy, hepatitis B vaccination. Follow the current Canadian Immunization Guide/NACI schedule for exact products, dosing intervals, and booster timing, since vaccine formulations and recommended intervals continue to evolve.^[1]

Vaso-occlusive crisis analgesia

Give parenteral opioids with monitoring for oversedation. Titrate to the level of pain reported, not to a fixed dose regardless of response — respiratory depression is rare when dosing is genuinely response-guided.

Drug	Dosage	Adverse effects	Drug interactions	Comments
Morphine	Adults/children, IV: 0.1-0.15 mg/kg, repeated roughly every 15-30 minutes to effect	Sedation, constipation, pruritus; all opioids share this class effect	Additive sedation with other CNS depressants	First-line; titrate rapidly and individualize upward for a patient with a known higher effective dose.
Hydromorphone	Adults/children, IV: 0.015-0.02 mg/kg, repeated roughly every 15-30 minutes to effect	Sedation, constipation, pruritus	Additive sedation with other CNS depressants	More potent per mg than morphine — use lower doses; a reasonable default for a known high opioid requirement.
Fentanyl	Adults/children, IV: 0.5-1 mcg/kg, repeated roughly every 30-60 minutes to effect	Chest wall rigidity with rapid high-dose push	Additive sedation with other CNS depressants; CYP3A4 inhibitors may potentiate effect	Minimal active-metabolite accumulation in renal impairment.
Ketorolac	Adults, IV/IM: 15-30 mg every 6 hours, maximum 5 days	Same as oral NSAIDs; cannot be dose-titrated once given	Same interaction profile as other NSAIDs (warfarin, antihypertensives, lithium, SSRIs)	Adjunct only; avoid or use cautiously with sickle cell nephropathy or acute kidney injury.
Diphenhydramine	Adults, PO/IV: 25-50 mg every 6 hours as needed	Sedation, additive with the opioid itself	Additive CNS depression with opioids/other sedatives	For opioid-induced pruritus, which is usually histamine-related rather than a true allergy.
Ondansetron	Adults, IV/PO: 4-8 mg every 8 hours as needed	Headache; QT prolongation at high doses	Additive QT effect with other QT-prolonging drugs	Preferred over a sedating antiemetic, which would compound opioid sedation.
Meperidine	Not recommended: Avoid for SCD pain crisis management	Seizures from normeperidine accumulation with repeated dosing	Potentially life-threatening serotonin syndrome with nonselective MAOIs	Avoid for vaso-occlusive crisis — repeated dosing across a crisis, or across multiple crises, is exactly the pattern that causes normeperidine accumulation.
Tramadol	Not recommended: As a primary agent for a genuine vaso-occlusive crisis	More nausea than other opioids; CYP2D6 ultra-rapid metabolizers at risk of respiratory depression	Serotonin syndrome risk with SSRIs/SNRIs/MAOIs	Not an appropriate first-line agent for genuinely severe crisis pain.

Iron chelation (transfusion-dependent patients)

Reserve for patients with confirmed transfusional iron overload, guided by serial ferritin and periodic cardiac/liver T2* MRI rather than ferritin alone.

Drug	Dosage	Adverse effects	Drug interactions	Comments
Deferasirox	Adults/children: Weight-based dose per current product labelling, titrated to ferritin/MRI response	GI upset, rash, transaminase elevation, renal impairment (monitor creatinine)	Reduces absorption of concurrent oral iron; interacts with UGT1A1 substrates	Once-daily oral chelator; the most widely used agent for transfusional iron overload in SCD.
Deferiprone	Adults/children: Weight-based dose per current product labelling, titrated to ferritin/MRI response	Agranulocytosis/neutropenia (requires weekly CBC monitoring), GI upset, arthralgia	Avoid combining with other drugs that cause neutropenia	An alternative or add-on oral chelator, particularly when cardiac iron overload is prominent.
Deferoxamine	Adults/children: Weight-based infusional dose per current product labelling, titrated to ferritin/MRI response	Ototoxicity, retinal toxicity, local injection-site reactions, growth restriction in children with excessive dosing	Avoid high-dose use with low ferritin (increased toxicity risk)	Subcutaneous or IV infusion; historically the standard agent, now often reserved for patients who cannot use an oral chelator or who need intensified chelation.

^[6]

Evidence note: Drug inventory, dosing, monitoring, and comments reflect current Canadian practice, cross-checked against the CanHaem Consensus Statement on the Care of Patients with Sickle Cell Disease in Canada, the 2014 NHLBI expert panel report, and the 2020 ASH sickle cell disease guidelines on pain and transfusion support.

References

Immunizations and Antimicrobial Prophylaxis — Canadian Hemoglobinopathy Association — Consensus Statement on the Care of Patients with Sickle Cell Disease in Canada. Canadian Hemoglobinopathy Association
Evidence-Based Management of Sickle Cell Disease: Expert Panel Report, 2014 — National Heart, Lung, and Blood Institute (NHLBI), U.S. National Institutes of Health. NHLBI, 2014
Acute Chest Syndrome — Canadian Hemoglobinopathy Association — Consensus Statement on the Care of Patients with Sickle Cell Disease in Canada. Canadian Hemoglobinopathy Association
Hydroxyurea — Canadian Hemoglobinopathy Association (Odame J, Okechukwu C, Kirby M) — Consensus Statement on the Care of Patients with Sickle Cell Disease in Canada. Version dated Feb 21, 2024
American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain — Blood Advances, American Society of Hematology (Brandow AM, Carroll CP, Creary S, et al.). Blood Adv 2020;4(12):2656-2701
American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support — Blood Advances, American Society of Hematology (Chou ST, Alsawas M, Fasano RM, et al.). Blood Adv 2020;4(2):327-355
Accelerated drug approvals and patient trust: impact of voxelotor and crizanlizumab for sickle cell disease — Blood Advances, American Society of Hematology (Karkoska K, Jacob SA, McGann PT). Blood Adv 2025;9(11):2857-2862

Professional reference only. Apply clinical judgment and verify patient-specific decisions against current authoritative guidance and product information.